Download PDF
Semin Neurol 2011; 31(3): 338-355
DOI: 10.1055/s-0031-1287655
© Thieme Medical Publishers

Vaccines and Neurologic Disease

James J. Sejvar1
  • 1Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
Further Information

Publication History

Publication Date:
30 September 2011 (online)

    Permissions and Reprints

ABSTRACT

Vaccines have undoubtedly been a medical milestone, preventing immeasurable morbidity and mortality from infectious diseases worldwide. Modern vaccines have tremendously reduced the global impact of numerous infections; they have succeeded in eliminating smallpox completely. However, the nature by which vaccines confer their protection—by stimulation of the immune system—means that in rare cases, adverse often immunologically mediated events may occur following vaccination. Some of the most severe of these involve the nervous system. The author provides an overview of the mechanisms of vaccinology, and describes the various vaccines available for particular neurologic illnesses. Possible neurologic adverse events following vaccinations, and the possible mechanisms of these events, are also discussed. Finally, procedures in place to ensure vaccine safety are reviewed.

KEYWORDS

Vaccines - encephalitis - virus - adverse events

REFERENCES

  • 1 Centers for Disease Control and Prevention (CDC) . Ten great public health achievements—United States, 1900-1999.  MMWR Morb Mortal Wkly Rep. 1999;  48 (12) 241-243
    PubMedGoogle Scholar
  • 2 World Health Organization .The Global Eradication of Smallpox: Final Report of the Global Commission for the Certification of Smallpox Eradication. Geneva: World Health Organization; 1980
    Google Scholar
  • 3 Riedel S. Edward Jenner and the history of smallpox and vaccination.  Proc (Bayl Univ Med Cent). 2005;  18 (1) 21-25 (Bayl Univ Med Cent)
    CrossrefPubMedGoogle Scholar
  • 4 Plotkin S A, Orenstein W, Offit P A Eds.. Vaccines. 5th ed. Philadelphia: Saunders; 2008
    Google Scholar
  • 5 Centers for Disease Control and Prevention . Recommended immunization schedules for persons aged 0–18 years—United States, 2011.  MMWR Morb Mortal Wkly Rep. 2011;  60 (5) 1-4
    PubMedGoogle Scholar
  • 6 Advisory Committee for Immunization Practices .ACIP Vaccine Recommendations. Atlanta, GA: Centers for Disease Control and Prevention; 2011
    Google Scholar
  • 7 WHO Expert Committee on Biological Standardization. Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs. Geneva: World Health Organization; 2005
    Google Scholar
  • 8 World Health Organization . Cholera vaccines: WHO position paper.  Wkly Epidemiol Rec. 2010;  85 (13) 117-128
    PubMedGoogle Scholar
  • 9 Centers for Disease Control and Prevention. Typhoid immunization.  MMWR Recomm Rep. 1994;  43 (RR-14)
    PubMedGoogle Scholar
  • 10 Centers for Disease Control and Prevention .Travelers' Health, Vaccination. Atlanta, GA: Centers for Disease Control and Prevention; 2009
    Google Scholar
  • 11 Paessler S, Weaver S C. Vaccines for Venezuelan equine encephalitis.  Vaccine. 2009;  27 (Suppl 4) D80-D85
    CrossrefPubMedGoogle Scholar
  • 12 Centers for Disease Control and Prevention. Advisory Committee for Immunization Practices. Updated Tdap Vaccine Recommendations from the ACIP, 2010. Atlanta, GA: Centers for Disease Control and Prevention; 2010
    Google Scholar
  • 13 Mandell G L, Bennett J E, Dolin R. Principles and Practice of Infectious Disease. 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2005
    Google Scholar
  • 14 Dalakas M C, Sever J L, Madden D L et al.. Late postpoliomyelitis muscular atrophy: clinical, virologic, and immunologic studies.  Rev Infect Dis. 1984;  6 (Suppl 2) S562-S567
    CrossrefPubMedGoogle Scholar
  • 15 Dalakas M C, Bartfeld H, Kurland L T. The postpolio syndrome: advances in the pathogenesis and treatment.  Ann N Y Acad Sci. 1995;  753 1-412
    CrossrefPubMedGoogle Scholar
  • 16 Nathanson N, Kew O M. From emergence to eradication: the epidemiology of poliomyelitis deconstructed.  Am J Epidemiol. 2010;  172 (11) 1213-1229
    CrossrefPubMedGoogle Scholar
  • 17 Centers for Disease Control and Prevention (CDC) . Certification of poliomyelitis eradication—the Americas, 1994.  MMWR Morb Mortal Wkly Rep. 1994;  43 (39) 720-722
    PubMedGoogle Scholar
  • 18 Centers for Disease Control and Prevention (CDC) . Progress toward interruption of wild poliovirus transmission - worldwide, 2009.  MMWR Morb Mortal Wkly Rep. 2010;  59 (18) 545-550
    PubMedGoogle Scholar
  • 19 Esteves K. Safety of oral poliomyelitis vaccine: results of a WHO enquiry.  Bull World Health Organ. 1988;  66 (6) 739-746
    PubMedGoogle Scholar
  • 20 Prevots D R, Sutter R W, Strebel P M, Weibel R E, Cochi S L. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Implications for estimating the risk of vaccine-associated disease.  Arch Pediatr Adolesc Med. 1994;  148 (5) 479-485
    CrossrefPubMedGoogle Scholar
  • 21 Wunner W H, Briggs D J. Rabies in the 21 century.  PLoS Negl Trop Dis. 2010;  4 (3) e591
    CrossrefPubMedGoogle Scholar
  • 22 Briggs D J. World Rabies Day: working together to make rabies history.  Vaccine. 2007;  25 6830-6831
    CrossrefPubMedGoogle Scholar
  • 23 Dodet B. Asian Rabies Expert Bureau (AREB) . An important date in rabies history.  Vaccine. 2007;  25 (52) 8647-8650
    CrossrefPubMedGoogle Scholar
  • 24 Culbertson C G, Peck Jr F B, Powell H M. Duck-embryo rabies vaccine; study of fixed virus vaccine grown in embryonated duck eggs and killed with beta-propiolactone (BPL).  J Am Med Assoc. 1956;  162 (15) 1373-1376
    CrossrefPubMedGoogle Scholar
  • 25 Fuenzalida E, Palacios R, Borgono J M. Antirabies antibody response in man to vaccine made from infected suckling-mouse brains.  Bull World Health Organ. 1964;  30 431-436
    PubMedGoogle Scholar
  • 26 World Health Organization . Rabies vaccines. WHO position paper.  Wkly Epidemiol Rec. 2007;  82 (49-50) 425-435
    PubMedGoogle Scholar
  • 27 Gubler D J. The global emergence/resurgence of arboviral diseases as public health problems.  Arch Med Res. 2002;  33 (4) 330-342
    CrossrefPubMedGoogle Scholar
  • 28 Wang S P. Japanese encephalitis in Taiwan: a review of recent studies.  Bull World Health Organ. 1964;  30 279-284
    PubMedGoogle Scholar
  • 29 Parida M, Dash P K, Tripathi N K et al.. Japanese Encephalitis Outbreak, India, 2005.  Emerg Infect Dis. 2006;  12 (9) 1427-1430
    CrossrefPubMedGoogle Scholar
  • 30 Richter R W, Shimojyo S. Neurologic sequelae of Japanese B encephalitis.  Neurology. 1961;  11 553-559
    CrossrefPubMedGoogle Scholar
  • 31 Grossberg S, Heyman A, Keehn R J. Neurologic sequelae of Japanese encephalitis. Report of a cooperative study.  Trans Am Neurol Assoc. 1962;  87 114-117
    PubMedGoogle Scholar
  • 32 Huy B V, Tu H C, Luan T V, Lindqvist R. Early mental and neurological sequelae after Japanese B encephalitis.  Southeast Asian J Trop Med Public Health. 1994;  25 (3) 549-553
    PubMedGoogle Scholar
  • 33 Baruah H C, Biswas D, Patgiri D, Mahanta J. Clinical outcome and neurological sequelae in serologically confirmed cases of Japanese encephalitis patients in Assam, India.  Indian Pediatr. 2002;  39 (12) 1143-1148
    PubMedGoogle Scholar
  • 34 Kuttner A G, Ts'un T. Encephalitis in north China. Results obtained with neutralization tests.  J Clin Invest. 1936;  15 (5) 525-530
    CrossrefPubMedGoogle Scholar
  • 35 Wilder-Smith A, Halstead S B. Japanese encephalitis: update on vaccines and vaccine recommendations.  Curr Opin Infect Dis. 2010;  23 (5) 426-431
    CrossrefPubMedGoogle Scholar
  • 36 Centers for Disease Control and Prevention . Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 1993;  42 (RR-1) 1-15
    PubMedGoogle Scholar
  • 37 Guess H A, Broughton D D, Melton III L J, Kurland L T. Population-based studies of varicella complications.  Pediatrics. 1986;  78 (4 Pt 2) 723-727
    PubMedGoogle Scholar
  • 38 Preblud S R. Varicella: complications and costs.  Pediatrics. 1986;  78 (4 Pt 2) 728-735
    PubMedGoogle Scholar
  • 39 Choo P W, Donahue J G, Manson J E, Platt R. The epidemiology of varicella and its complications.  J Infect Dis. 1995;  172 (3) 706-712
    CrossrefPubMedGoogle Scholar
  • 40 Mueller N H, Gilden D H, Cohrs R J, Mahalingam R, Nagel M A. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency.  Neurol Clin. 2008;  26 (3) 675-697 viii viii
    CrossrefPubMedGoogle Scholar
  • 41 Marin M, Güris D, Chaves S S, Schmid S, Seward J F. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC) . Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2007;  56 (RR-4, RR-04) 1-40
    PubMedGoogle Scholar
  • 42 Marin M, Broder K R, Temte J L, Snider D E, Seward J F. Centers for Disease Control and Prevention (CDC) . Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2010;  59 (RR-3) 1-12
    PubMedGoogle Scholar
  • 43 Plotkin S A, Starr S E, Connor K, Morton D. Zoster in normal children after varicella vaccine.  J Infect Dis. 1989;  159 (5) 1000-1001
    CrossrefPubMedGoogle Scholar
  • 44 White C J. Clinical trials of varicella vaccine in healthy children.  Infect Dis Clin North Am. 1996;  10 (3) 595-608
    CrossrefPubMedGoogle Scholar
  • 45 Harpaz R, Ortega-Sanchez I R, Seward J F. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC) . Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2008;  57 (RR-5) 1-30 quiz CE2-CE4
    PubMedGoogle Scholar
  • 46 Oxman M N. Zoster vaccine: current status and future prospects.  Clin Infect Dis. 2010;  51 (2) 197-213
    CrossrefPubMedGoogle Scholar
  • 47 Sanford M, Keating G M. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.  Drugs Aging. 2010;  27 (2) 159-176
    CrossrefPubMedGoogle Scholar
  • 48 Advisory Committee on Immunization Practices . Recommended adult immunization schedule: United States, 2011.  Ann Intern Med. 2011;  154 (3) 168-173
    PubMedGoogle Scholar
  • 49 Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.  Ann Intern Med. 2006;  145 (5) 317-325
    PubMedGoogle Scholar
  • 50 Pellissier J M, Brisson M, Levin M J. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.  Vaccine. 2007;  25 (49) 8326-8337
    CrossrefPubMedGoogle Scholar
  • 51 Rothberg M B, Virapongse A, Smith K J. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.  Clin Infect Dis. 2007;  44 (10) 1280-1288
    CrossrefPubMedGoogle Scholar
  • 52 Rosenstein N E, Perkins B A, Stephens D S, Popovic T, Hughes J M. Meningococcal disease.  N Engl J Med. 2001;  344 (18) 1378-1388
    CrossrefPubMedGoogle Scholar
  • 53 Molesworth A M, Thomson M C, Connor S J et al.. Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa.  Trans R Soc Trop Med Hyg. 2002;  96 (3) 242-249
    CrossrefPubMedGoogle Scholar
  • 54 Khatami A, Pollard A J. The epidemiology of meningococcal disease and the impact of vaccines.  Expert Rev Vaccines. 2010;  9 (3) 285-298
    CrossrefPubMedGoogle Scholar
  • 55 Rosenstein N E, Perkins B A. Update on Haemophilus influenzae serotype b and meningococcal vaccines.  Pediatr Clin North Am. 2000;  47 (2) 337-352, vi vi
    CrossrefPubMedGoogle Scholar
  • 56 Cartwright K, Noah N, Peltola H. Meningococcal Disease Advisory Board . Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000.  Vaccine. 2001;  19 (31) 4347-4356
    CrossrefPubMedGoogle Scholar
  • 57 Rosenstein N E, Perkins B A, Stephens D S et al.. The changing epidemiology of meningococcal disease in the United States, 1992-1996.  J Infect Dis. 1999;  180 (6) 1894-1901
    CrossrefPubMedGoogle Scholar
  • 58 Pollard A J, Levin M. Vaccines for prevention of meningococcal disease.  Pediatr Infect Dis J. 2000;  19 (4) 333-344, quiz 345
    PubMedGoogle Scholar
  • 59 Pollard A J, Maiden M C. Epidemic meningococcal disease in sub-Saharan Africa—towards a sustainable solution?.  Lancet Infect Dis. 2003;  3 (2) 68-70
    CrossrefPubMedGoogle Scholar
  • 60 Pollard A J. Global epidemiology of meningococcal disease and vaccine efficacy.  Pediatr Infect Dis J. 2004;  23 (12, Suppl) S274-S279
    PubMedGoogle Scholar
  • 61 Centers for Disease Control and Prevention (CDC) . Updated recommendations for use of meningococcal conjugate vaccines — Advisory Committee on Immunization Practices (ACIP), 2010.  MMWR Morb Mortal Wkly Rep. 2011;  60 (3) 72-76
    PubMedGoogle Scholar
  • 62 World Health Organization . Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines.  Wkly Epidemiol Rec. 2002;  77 (40) 331-339
    PubMedGoogle Scholar
  • 63 Brook I. Current concepts in the management of Clostridium tetani infection.  Expert Rev Anti Infect Ther. 2008;  6 (3) 327-336
    CrossrefPubMedGoogle Scholar
  • 64 Pascual F B, McGinley E L, Zanardi L R, Cortese M M, Murphy T V. Tetanus surveillance—United States, 1998–2000.  MMWR Surveill Summ. 2003;  52 (3) 1-8
    PubMedGoogle Scholar
  • 65 Galazka A, Bermingham M, Kurian M, Gasse F. Tetanus. In: Murray C JL, Lopez A D, Mathers C D, eds. The Global Epidemiology of Infectious Diseases. Geneva: World Health Organization; 2004: 151-199
    Google Scholar
  • 66 Gardner P. Issues related to the decennial tetanus-diphtheria toxoid booster recommendations in adults.  Infect Dis Clin North Am. 2001;  15 (1) 143-153
    CrossrefPubMedGoogle Scholar
  • 67 Centers for Disease Control and Prevention (CDC) . Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010.  MMWR Morb Mortal Wkly Rep. 2011;  60 (1) 13-15
    PubMedGoogle Scholar
  • 68 Kretsinger K, Broder K R, Cortese M M Centers for Disease Control and Prevention et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.  MMWR Recomm Rep. 2006;  55 (RR-17) 1-37
    PubMedGoogle Scholar
  • 69 Roper M H, Vandelaer J H, Gasse F L. Maternal and neonatal tetanus.  Lancet. 2007;  370 (9603) 1947-1959
    CrossrefPubMedGoogle Scholar
  • 70 Garren H. A DNA vaccine for multiple sclerosis.  Expert Opin Biol Ther. 2008;  8 (10) 1539-1550
    CrossrefPubMedGoogle Scholar
  • 71 Hickey M J, Malone C C, Erickson K L et al.. Cellular and vaccine therapeutic approaches for gliomas.  J Transl Med. 2010;  8 100
    CrossrefPubMedGoogle Scholar
  • 72 A vaccine against meningitis in Africa.  Lancet Infect Dis. 2011;  11 (1) 1
    CrossrefPubMedGoogle Scholar
  • 73 Biedenbender R, Bevilacqua J, Gregg A M, Watson M, Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults.  J Infect Dis. 2011;  203 (1) 75-84
    CrossrefPubMedGoogle Scholar
  • 74 Smith L A. Botulism and vaccines for its prevention.  Vaccine. 2009;  27 (Suppl 4) D33-D39
    CrossrefPubMedGoogle Scholar
  • 75 Rivers TMSF, Schwentker F F. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys.  J Exp Med. 1935;  61 (5) 689-702
    CrossrefPubMedGoogle Scholar
  • 76 Vital C, Vital A, Gbikpi-Benissan G et al.. Postvaccinal inflammatory neuropathy: peripheral nerve biopsy in 3 cases.  J Peripher Nerv Syst. 2002;  7 (3) 163-167
    CrossrefPubMedGoogle Scholar
  • 77 Levin M C, Krichavsky M, Berk J et al.. Neuronal molecular mimicry in immune-mediated neurologic disease.  Ann Neurol. 1998;  44 (1) 87-98
    CrossrefPubMedGoogle Scholar
  • 78 Kalume F, Lee S M, Morcos Y, Callaway J C, Levin M C. Molecular mimicry: cross-reactive antibodies from patients with immune-mediated neurologic disease inhibit neuronal firing.  J Neurosci Res. 2004;  77 (1) 82-89
    CrossrefPubMedGoogle Scholar
  • 79 Pou M A, Diaz-Torne C, Vidal S et al.. Development of autoimmune diseases after vaccination.  J Clin Rheumatol. 2008;  14 (4) 243-244
    CrossrefPubMedGoogle Scholar
  • 80 Orbach H, Agmon-Levin N, Zandman-Goddard G. Vaccines and autoimmune diseases of the adult.  Discov Med. 2010;  9 (45) 90-97
    PubMedGoogle Scholar
  • 81 Johnson R Ed.. Postinfectious Demyelinating Disease. Philadelphia, New York: Lippincott-Raven; 1998: 181-211
    Google Scholar
  • 82 Fenichel G M. Neurological complications of immunization.  Ann Neurol. 1982;  12 (2) 119-128
    CrossrefPubMedGoogle Scholar
  • 83 Miravalle A, Biller J, Schnitzler E, Bonwit A. Neurological complications following vaccinations.  Neurol Res. 2010;  32 (3) 285-292
    CrossrefPubMedGoogle Scholar
  • 84 Piyasirisilp S, Schmeckpeper B J, Chandanayingyong D, Hemachudha T, Griffin D E. Association of HLA and T-cell receptor gene polymorphisms with Semple rabies vaccine-induced autoimmune encephalomyelitis.  Ann Neurol. 1999;  45 (5) 595-600
    CrossrefPubMedGoogle Scholar
  • 85 Hemachudha T, Phanuphak P, Johnson R T, Griffin D E, Ratanavongsiri J, Siriprasomsup W. Neurologic complications of Semple-type rabies vaccine: clinical and immunologic studies.  Neurology. 1987;  37 (4) 550-556
    CrossrefPubMedGoogle Scholar
  • 86 Hemachudha T, Griffin D E, Giffels J J, Johnson R T, Moser A B, Phanuphak P. Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination.  N Engl J Med. 1987;  316 (7) 369-374
    CrossrefPubMedGoogle Scholar
  • 87 Hemachudha T, Griffin D E, Chen W W, Johnson R T. Immunologic studies of rabies vaccination-induced Guillain-Barré syndrome.  Neurology. 1988;  38 (3) 375-378
    CrossrefPubMedGoogle Scholar
  • 88 Takahashi H, Pool V, Tsai T F, Chen R T. The VAERS Working Group . Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States.  Vaccine. 2000;  18 (26) 2963-2969
    CrossrefPubMedGoogle Scholar
  • 89 Swicowa K, Mostowiec S. [Neurological complications following smallpox vaccination].  Pediatr Pol. 1964;  39 1207-1211
    PubMedGoogle Scholar
  • 90 Siegert R. [Behaviour of vaccinia virus in central nervous system injury caused by vaccine. II. Virological studies in the central nervous system].  Dtsch Med Wochenschr. 1957;  82 (49) 2061-2065
    Article in Thieme ConnectPubMedGoogle Scholar
  • 91 Siegert R. [Behaviour of vaccinia virus in central nervous injury caused by vaccine. I. Virological studies at the inoculation site, in the regional lymph nodes and in the blood].  Dtsch Med Wochenschr. 1957;  82 (48) 2021-2024
    Article in Thieme ConnectPubMedGoogle Scholar
  • 92 Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child.  JAMA. 1966;  198 (6) 671-672
    CrossrefPubMedGoogle Scholar
  • 93 McMahon A W, Eidex R B, Marfin A A Yellow Fever Working Group et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases.  Vaccine. 2007;  25 (10) 1727-1734
    CrossrefPubMedGoogle Scholar
  • 94 Lista F, Faggioni G, Peragallo M S et al.. Molecular analysis of early postvaccine mumps-like disease in Italian military recruits.  JAMA. 2002;  287 (9) 1114-1115
    CrossrefPubMedGoogle Scholar
  • 95 Neustadt R E, Fineberg H V. The Swine Flu Affair. Honolulu: University Press of the Pacific; 2005
    Google Scholar
  • 96 Schonberger L B, Bregman D J, Sullivan-Bolyai J Z et al.. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977.  Am J Epidemiol. 1979;  110 (2) 105-123
    PubMedGoogle Scholar
  • 97 Breman J G, Hayner N S. Guillain-Barré syndrome and its relationship to swine influenza vaccination in Michigan, 1976-1977.  Am J Epidemiol. 1984;  119 (6) 880-889
    PubMedGoogle Scholar
  • 98 Langmuir A D, Bregman D J, Kurland L T, Nathanson N, Victor M. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines.  Am J Epidemiol. 1984;  119 (6) 841-879
    CrossrefPubMedGoogle Scholar
  • 99 Safranek T J, Lawrence D N, Kurland L T Expert Neurology Group et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study.  Am J Epidemiol. 1991;  133 (9) 940-951
    PubMedGoogle Scholar
  • 100 Hurwitz E S, Schonberger L B, Nelson D B, Holman R C. Guillain-Barré syndrome and the 1978-1979 influenza vaccine.  N Engl J Med. 1981;  304 (26) 1557-1561
    CrossrefPubMedGoogle Scholar
  • 101 Kaplan J E, Katona P, Hurwitz E S, Schonberger L B. Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination.  JAMA. 1982;  248 (6) 698-700
    CrossrefPubMedGoogle Scholar
  • 102 Kaplan J E, Schonberger L B, Hurwitz E S, Katona P. Guillain-Barré syndrome in the United States, 1978-1981: additional observations from the national surveillance system.  Neurology. 1983;  33 (5) 633-637
    CrossrefPubMedGoogle Scholar
  • 103 Roscelli J D, Bass J W, Pang L. Guillain-Barré syndrome and influenza vaccination in the US Army, 1980-1988.  Am J Epidemiol. 1991;  133 (9) 952-955
    PubMedGoogle Scholar
  • 104 Chen R T, Kent J, Rhodes P, Simon P, Schonberger L. Investigation of a possible association between influenza vaccination and Guillain-Barre syndrome in the United States, 1990–1991.  Post Mark Surveill. 1992;  6 (1) 5-6
    PubMedGoogle Scholar
  • 105 Lasky T, Terracciano G J, Magder L et al.. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.  N Engl J Med. 1998;  339 (25) 1797-1802
    CrossrefPubMedGoogle Scholar
  • 106 Haber P, DeStefano F, Angulo F J et al.. Guillain-Barré syndrome following influenza vaccination.  JAMA. 2004;  292 (20) 2478-2481
    CrossrefPubMedGoogle Scholar
  • 107 Juurlink D N, Stukel T A, Kwong J et al.. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study.  Arch Intern Med. 2006;  166 (20) 2217-2221
    CrossrefPubMedGoogle Scholar
  • 108 Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database.  Am J Epidemiol. 2009;  169 (3) 382-388
    PubMedGoogle Scholar
  • 109 Nachamkin I, Shadomy S V, Moran A P et al.. Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome.  J Infect Dis. 2008;  198 (2) 226-233
    CrossrefPubMedGoogle Scholar
  • 110 Lopez Adaros H, Held J R. Guillain-Barré syndrome associated with immunization against rabies: epidemiological aspects.  Res Publ Assoc Res Nerv Ment Dis. 1971;  49 178-186
    PubMedGoogle Scholar
  • 111 Pollard J D, Selby G. Relapsing neuropathy due to tetanus toxoid. Report of a case.  J Neurol Sci. 1978;  37 (1-2) 113-125
    CrossrefPubMedGoogle Scholar
  • 112 Tuttle J, Chen R T, Rantala H, Cherry J D, Rhodes P H, Hadler S. The risk of Guillain-Barré syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States.  Am J Public Health. 1997;  87 (12) 2045-2048
    CrossrefPubMedGoogle Scholar
  • 113 Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barré syndrome.  Drug Saf. 2009;  32 (4) 309-323
    CrossrefPubMedGoogle Scholar
  • 114 Stratton K, Almario D A, McCormick M C. Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders. Washington, DC: Institute of Medicine; 2002
    Google Scholar
  • 115 Ascherio A, Zhang S M, Hernán M A et al.. Hepatitis B vaccination and the risk of multiple sclerosis.  N Engl J Med. 2001;  344 (5) 327-332
    CrossrefPubMedGoogle Scholar
  • 116 Confavreux C, Suissa S, Saddier P, Bourdès V, Vukusic S. Vaccines in Multiple Sclerosis Study Group . Vaccinations and the risk of relapse in multiple sclerosis.  N Engl J Med. 2001;  344 (5) 319-326
    CrossrefPubMedGoogle Scholar
  • 117 DeStefano F, Verstraeten T, Chen R T. Hepatitis B vaccine and risk of multiple sclerosis.  Expert Rev Vaccines. 2002;  1 (4) 461-466
    CrossrefPubMedGoogle Scholar
  • 118 Harris C, Lee K. Acute disseminated encephalomyelitis.  J Neurosci Nurs. 2007;  39 (4) 208-212
    CrossrefPubMedGoogle Scholar
  • 119 Wingerchuk D M. Acute disseminated encephalomyelitis: distinction from multiple sclerosis and treatment issues.  Adv Neurol. 2006;  98 303-318
    PubMedGoogle Scholar
  • 120 Young N P, Weinshenker B G, Lucchinetti C F. Acute disseminated encephalomyelitis: current understanding and controversies.  Semin Neurol. 2008;  28 (1) 84-94
    Article in Thieme ConnectPubMedGoogle Scholar
  • 121 Tenembaum S N. Disseminated encephalomyelitis in children.  Clin Neurol Neurosurg. 2008;  110 (9) 928-938
    CrossrefPubMedGoogle Scholar
  • 122 Murthy S N, Faden H S, Cohen M E, Bakshi R. Acute disseminated encephalomyelitis in children.  Pediatrics. 2002;  110 (2 Pt 1) e21
    CrossrefPubMedGoogle Scholar
  • 123 Mihai C, Jubelt B. Post-infectious encephalomyelitis.  Curr Neurol Neurosci Rep. 2005;  5 (6) 440-445
    CrossrefPubMedGoogle Scholar
  • 124 Murphy J, Austin J. Spontaneous infection or vaccination as cause of acute disseminated encephalomyelitis.  Neuroepidemiology. 1985;  4 (3) 138-145
    CrossrefPubMedGoogle Scholar
  • 125 Solomon T. New vaccines for Japanese encephalitis.  Lancet Neurol. 2008;  7 (2) 116-118
    CrossrefPubMedGoogle Scholar
  • 126 Moore Z S, Seward J F, Lane J M. Smallpox.  Lancet. 2006;  367 (9508) 425-435
    CrossrefPubMedGoogle Scholar
  • 127 Lane J M, Ruben F L, Neff J M, Millar J D. Complications of smallpox vaccination, 1968.  N Engl J Med. 1969;  281 (22) 1201-1208
    CrossrefPubMedGoogle Scholar
  • 128 De Vries E. Post Vaccinial Perivenous Encephalitis. Amsterdam: Elsevier; 1960
    Google Scholar
  • 129 Miller D L, Ross E M, Alderslade R, Bellman M H, Rawson N S. Pertussis immunisation and serious acute neurological illness in children.  Br Med J (Clin Res Ed). 1981;  282 (6276) 1595-1599
    CrossrefPubMedGoogle Scholar
  • 130 Miller D C, Wadsworth M J, Ross E M. Pertussis vaccine and severe acute neurological illnesses. Response to a recent review by members of the NCES team.  Vaccine. 1989;  7 (6) 487-489
    CrossrefPubMedGoogle Scholar
  • 131 Safety of pertussis vaccine.  Lancet. 1990;  335 (8690) 655-656
    CrossrefPubMedGoogle Scholar
  • 132 Griffin M R, Ray W A, Mortimer E A, Fenichel G M, Schaffner W. Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine.  JAMA. 1990;  263 (12) 1641-1645
    CrossrefPubMedGoogle Scholar
  • 133 Stratton K R, How C J, Johnston R B. DPT Vaccine and Chronic Nervous System Dysfunction: A New Analysis. Washington, DC: National Academy Press; 1994
    Google Scholar
  • 134 Currenti S A. Understanding and determining the etiology of autism.  Cell Mol Neurobiol. 2010;  30 (2) 161-171
    CrossrefPubMedGoogle Scholar
  • 135 Wakefield A J, Murch S H, Anthony A et al.. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children.  Lancet. 1998;  351 (9103) 637-641
    CrossrefPubMedGoogle Scholar
  • 136 Farrington C P, Miller E, Taylor B. MMR and autism: further evidence against a causal association.  Vaccine. 2001;  19 (27) 3632-3635
    CrossrefPubMedGoogle Scholar
  • 137 Smeeth L, Hall A J, Fombonne E, Rodrigues L C, Huang X, Smith P G. A case-control study of autism and mumps-measles-rubella vaccination using the general practice research database: design and methodology.  BMC Public Health. 2001;  1 2
    CrossrefPubMedGoogle Scholar
  • 138 Hornig M, Briese T, Buie T et al.. Lack of association between measles virus vaccine and autism with enteropathy: a case-control study.  PLoS ONE. 2008;  3 (9) e3140
    CrossrefPubMedGoogle Scholar
  • 139 Bedford H E, Elliman D A. MMR vaccine and autism.  BMJ. 2010;  340 c655
    CrossrefPubMedGoogle Scholar
  • 140 Retraction—Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children.  Lancet. 2010;  375 (9713) 445
    CrossrefPubMedGoogle Scholar
  • 141 American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Environmental Health . Thimerosal in vaccines—An interim report to clinicians.  Pediatrics. 1999;  104 (3 Pt 1) 570-574
    CrossrefPubMedGoogle Scholar
  • 142 Madsen K M, Lauritsen M B, Pedersen C B et al.. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data.  Pediatrics. 2003;  112 (3 Pt 1) 604-606
    CrossrefPubMedGoogle Scholar
  • 143 Stehr-Green P, Tull P, Stellfeld M, Mortenson P B, Simpson D. Autism and thimerosal-containing vaccines: lack of consistent evidence for an association.  Am J Prev Med. 2003;  25 (2) 101-106
    CrossrefPubMedGoogle Scholar
  • 144 Stratton K, Gable A, McCormick M C. Immunization Safety Review: Thimerosal-containing vaccines and neurodevelopmental disorders. Washington, DC: National Academy Press; 2001
    Google Scholar
  • 145 Pritchard J, Mukherjee R, Hughes R A. Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation.  J Neurol Neurosurg Psychiatry. 2002;  73 (3) 348-349
    CrossrefPubMedGoogle Scholar
  • 146 Kuitwaard K, van Koningsveld R, Ruts L, Jacobs B C, van Doorn P A. Recurrent Guillain-Barré syndrome.  J Neurol Neurosurg Psychiatry. 2009;  80 (1) 56-59
    CrossrefPubMedGoogle Scholar
  • 147 Rutschmann O T, McCrory D C, Matchar D B. Immunization Panel of the Multiple Sclerosis Council for Clinical Practice Guidelines . Immunization and MS: a summary of published evidence and recommendations.  Neurology. 2002;  59 (12) 1837-1843
    CrossrefPubMedGoogle Scholar
  • 148 Fiore A E, Uyeki T M, Broder K Centers for Disease Control and Prevention (CDC) et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.  MMWR Recomm Rep. 2010;  59 (RR-8) 1-62
    PubMedGoogle Scholar
  • 149 Broder K R, Cortese M M, Iskander J K Advisory Committee on Immunization Practices (ACIP) et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2006;  55 (RR-3) 1-34
    PubMedGoogle Scholar
  • 150 Chen R T, Rastogi S C, Mullen J R et al.. The vaccine adverse event reporting system (VAERS).  Vaccine. 1994;  12 (6) 542-550
    CrossrefPubMedGoogle Scholar
  • 151 Singleton J A, Lloyd J C, Mootrey G T, Salive M E, Chen R T. VAERS Working Group . An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system.  Vaccine. 1999;  17 (22) 2908-2917
    CrossrefPubMedGoogle Scholar
  • 152 Chen R T, Glasser J W, Rhodes P H The Vaccine Safety Datalink Team et al. Vaccine safety datalink project: a new tool for improving vaccine safety monitoring in the United States.  Pediatrics. 1997;  99 (6) 765-773
    CrossrefPubMedGoogle Scholar
  • 153 Greene S K, Kulldorff M, Lewis E M et al.. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project.  Am J Epidemiol. 2010;  171 (2) 177-188
    CrossrefPubMedGoogle Scholar
  • 154 Perkins F T. Safety of vaccines.  Br Med Bull. 1969;  25 (2) 208-212
    PubMedGoogle Scholar
  • 155 Bohlke K, Davis R L, Marcy S M Vaccine Safety Datalink Team et al. Risk of anaphylaxis after vaccination of children and adolescents.  Pediatrics. 2003;  112 (4) 815-820
    CrossrefPubMedGoogle Scholar
  • 156 Fisher M C. Vaccine safety.  Pediatr Infect Dis J. 2008;  27 (9) 827-830
    PubMedGoogle Scholar
  • 157 Demirjian A, Levy O. Safety and efficacy of neonatal vaccination.  Eur J Immunol. 2009;  39 (1) 36-46
    CrossrefPubMedGoogle Scholar
  • 158 Lopalco P L, Johansen K, Ciancio B, De Carvalho Gomes H, Kramarz P, Giesecke J. Monitoring and assessing vaccine safety: a European perspective.  Expert Rev Vaccines. 2010;  9 (4) 371-380
    CrossrefPubMedGoogle Scholar

James J SejvarM.D. 

Neuroepidemiologist, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention

1600 Clifton Road, Mailstop A-39, Atlanta, GA 30333

Email: zea3@cdc.gov